NewAmsterdam Pharma Co N.V. (NAMS) · Sep 21, 2026 · Other events

NewAmsterdam wins first EU approval for obicetrapib, but PREVAIL still matters

EU approval — First worldwide approval; mid-teens € millions in milestone payments triggered

EU approval gives NewAmsterdam its first commercial foothold and triggers milestone cash, while the pivotal PREVAIL outcomes trial remains unresolved.

NewAmsterdam is moving obicetrapib from a late-stage clinical program toward commercialization: the oral LDL-lowering therapy targets high-risk patients who remain inadequately controlled or cannot tolerate existing treatments, with Menarini responsible for European commercialization. The filing clears the biggest near-term regulatory hurdle. The European Commission approved both Ubeslo monotherapy and the Evlarco fixed-dose combination across the EU, Iceland, Liechtenstein, and Norway—the first worldwide regulatory approval for obicetrapib. 〔0〕 This is a genuine business advance, not just another positive trial update: the company now has an approved product and a partner positioned to launch it in Europe. The economics begin immediately, although the cash impact is only partly specified. The approval triggers milestone payments in the mid-teens of millions of euros, while NewAmsterdam retains tiered double-digit royalties on European net sales and potential additional milestones of up to €833 million. Because the European Commission decision had already been telegraphed by the positive CHMP opinion and was expected in the second half of 2026, the direction was partly known; the new information is the completed approval and the immediate milestone trigger. Approval does not finish the clinical story. The authorization requires a post-authorization efficacy study tied to the final results of PREVAIL, the large cardiovascular-outcomes trial, so the commercial launch now runs alongside a still-important test of whether LDL reduction translates into fewer cardiovascular events. 〔1〕 PREVAIL’s interim analysis is planned for the fourth quarter of 2026, with results expected in the first quarter of 2027. Bottom line: This is a major transition from development to commercialization and materially de-risks the European path, but PREVAIL remains the next decisive proof point for the broader obicetrapib opportunity.

What to watch next

PREVAIL interim analysis, 4Q26; results expected 1Q27

Original filing on SEC EDGAR

More NewAmsterdam Pharma Co N.V. news

NewAmsterdam wins first EU approval for obicetrapib, but PREVAIL still matters | NAMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.